APA (7th ed.) Citation

Ruiz Seco, M. P., Paño Pardo, J. R., Schoergenhofer, C., Dings, C., Lehr, T., Herth, F., . . . Hoeger, T. (2024). Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial. EClinicalMedicine, 77, . https://doi.org/10.1016/j.eclinm.2024.102879

Chicago Style (17th ed.) Citation

Ruiz Seco, Maria Pilar, et al. "Efficacy and Safety of Asunercept, a CD95L-selective Inhibitor, in Hospitalised Patients with Moderate-to-severe COVID-19: ASUNCTIS, a Multicentre, Randomised, Open-label, Controlled, Phase 2 Trial." EClinicalMedicine 77 (2024). https://doi.org/10.1016/j.eclinm.2024.102879.

MLA (9th ed.) Citation

Ruiz Seco, Maria Pilar, et al. "Efficacy and Safety of Asunercept, a CD95L-selective Inhibitor, in Hospitalised Patients with Moderate-to-severe COVID-19: ASUNCTIS, a Multicentre, Randomised, Open-label, Controlled, Phase 2 Trial." EClinicalMedicine, vol. 77, 2024, https://doi.org/10.1016/j.eclinm.2024.102879.